Profile

James M. Olson, MD, PhD

James M. Olson, MD, PhD

Hematology-Oncology

On staff since July 1999

Academic Title: Professor

Research Center: Center for Clinical and Translational Research

James M. Olson, MD, PhD, is attending physician at Seattle Childrens Hospital and member of Fred Hutchinson Cancer Research Center (FHCRC); he is professor of Pediatric Hematology-Oncology and adjunct professor of Pathology at the University of Washington School of Medicine and on the faculty in the Program in Molecular and Cellular Biology, the Program in Neurobiology and Behavior, and the Center for Nanotechnology.

He serves as assistant program head of the pediatric oncology program at FHCRC and has mentored more than 30 graduate students and postdoctoral research fellows. He is chair of a national phase III clinical trial for high-risk medulloblastoma/PNET patients and member of the COG Biology and Translational Research Committee. Olson is principal investigator on six projects that focus on developing effective new therapies for pediatric brain tumors, methods that allow surgeons to better visualize the border of brain cancer and normal brain, and the molecular mechanisms of brain development.

Making A Difference

  • Clues to Brain Growth Found

    The discovery of mutations in genes that help regulate brain growth could lead to better treatments for brain disorders and other conditions, including cancer, autism and epilepsy. ... cont.

Overview

Board Certification(s)

Pediatric Hematology-Oncology

Medical/Professional School

University of Michigan Medical School, Ann Arbor

Residency

Pediatrics, University of Washington School of Medicine, Seattle

Fellowship

Pediatric Hematology-Oncology, University of Washington School of Medicine, Seattle

Research Description

I am principal investigator on six projects that focus on developing effective new therapies for pediatric brain tumors, methods that allow surgeons to better visualize the border of brain cancer and normal brain, the molecular mechanisms of cerebellar development and genetic-based endpoints for neuro-degenerative diseases.

A study led by my team and I showed that tumor paint is 500 times better than a standard MRI at helping surgeons distinguish between cancer cells and normal tissue. Our team developed the paint, which is currently being studied in mice models, from a scorpion-derived peptide called chlorotoxin.

Research Focus Area

Cancer

Awards and Honors

Award Name Award Description Awarded By Award Date
Medical Scientist Training Program Fellow
University of Michigan Regents Fellowship
Medical Student Research Program Award
Midwest Student Medical Research Forum XVII Award
Duncan McCarthy Award for Pharmacology Research
Nu Sigma Nu Medical Fraternity Scholarship in International Health
American Academy of Pediatrics Resident Research Award
Emily Dorfman Fellow, American Brain Tumor Association
Burroughs Wellcome Career Award in Biomedical Sciences
Child Health Research Center New Investigator Award
Children's Oncology Group Young Investigators Award
Damon Runyon Clinical Investigator Award

Publications

  • Dey J, Dubuc AM, Pedro KD, Thirstrup D, Mecham B, Northcott PA, Wu X, Shih D, Tapscott SJ, LeBlanc M, Taylor MD, Olson JM
    MyoD is a tumor suppressor gene in medulloblastoma.
    Cancer research , 2013 Nov. : 73(22)6828-37
  • Hubert CG, Bradley RK, Ding Y, Toledo CM, Herman J, Skutt-Kakaria K, Girard EJ, Davison J, Berndt J, Corrin P, Hardcastle J, Basom R, Delrow JJ, Webb T, Pollard SM, Lee J, Olson JM, Paddison PJ
    Genome-wide RNAi screens in human brain tumor isolates reveal a novel viability requirement for PHF5A.
    Genes and development , 2013 May : 27(9)1032-45
  • Aref D, Moffatt CJ, Agnihotri S, Ramaswamy V, Dubuc AM, Northcott PA, Taylor MD, Perry A, Olson JM, Eberhart CG, Croul SE
    Canonical TGF- pathway activity is a predictor of SHH-driven medulloblastoma survival and delineates putative precursors in cerebellar development.
    Brain pathology (Zurich, Switzerland) , 2013 Mar. : 23(2)178-91
  • Ding Y, Hubert CG, Herman J, Corrin P, Toledo CM, Skutt-Kakaria K, Vazquez J, Basom R, Zhang B, Risler JK, Pollard SM, Nam DH, Delrow JJ, Zhu J, Lee J, DeLuca J, Olson JM, Paddison PJ
    Cancer-Specific requirement for BUB1B/BUBR1 in human brain tumor isolates and genetically transformed cells.
    Cancer discovery , 2013 Feb. : 3(2)198-211
  • Lee SJ, Lindsey S, Graves B, Yoo S, Olson JM, Langhans SA
    Sonic hedgehog-induced histone deacetylase activation is required for cerebellar granule precursor hyperplasia in medulloblastoma.
    PloS one , 2013 : 8(8)e71455
  • Dey J, Ditzler S, Knoblaugh SE, Hatton BA, Schelter JM, Cleary MA, Mecham B, Rorke-Adams LB, Olson JM
    A distinct Smoothened mutation causes severe cerebellar developmental defects and medulloblastoma in a novel transgenic mouse model.
    Molecular and cellular biology , 2012 Oct. : 32(20)4104-15
  • Northcott PA, Shih DJ, Peacock J, Garzia L, Morrissy AS, Zichner T, Stütz AM, Korshunov A, Reimand J, Schumacher SE, Beroukhim R, Ellison DW, Marshall CR, Lionel AC, Mack S, Dubuc A, Yao Y, Ramaswamy V, Luu B, Rolider A, Cavalli FM, Wang X, Remke M, Wu X, Chiu RY, Chu A, Chuah E, Corbett RD, Hoad GR, Jackman SD, Li Y, Lo A, Mungall KL, Nip KM, Qian JQ, Raymond AG, Thiessen NT, Varhol RJ, Birol I, Moore RA, Mungall AJ, Holt R, Kawauchi D, Roussel MF, Kool M, Jones DT, Witt H, Fernandez-L A, Kenney AM, Wechsler-Reya RJ, Dirks P, Aviv T, Grajkowska WA, Perek-Polnik M, Haberler CC, Delattre O, Reynaud SS, Doz FF, Pernet-Fattet SS, Cho BK, Kim SK, Wang KC, Scheurlen W, Eberhart CG, Fèvre-Montange M, Jouvet A, Pollack IF, Fan X, Muraszko KM, Gillespie GY, Di Rocco C, Massimi L, Michiels EM, Kloosterhof NK, French PJ, Kros JM, Olson JM, Ellenbogen RG, Zitterbart K, Kren L, Thompson RC, Cooper MK, Lach B, McLendon RE, Bigner DD, Fontebasso A, Albrecht S, Jabado N, Lindsey JC, Bailey S, Gupta N, Weiss WA, Bognár L, Klekner A, Van Meter TE, Kumabe T, Tominaga T, Elbabaa SK, Leonard JR, Rubin JB, Liau LM, Van Meir EG, Fouladi M, Nakamura H, Cinalli G, Garami M, Hauser P, Saad AG, Iolascon A, Jung S, Carlotti CG, Vibhakar R, Ra YS, Robinson S, Zollo M, Faria CC, Chan JA, Levy ML, Sorensen PH, Meyerson M, Pomeroy SL, Cho YJ, Bader GD, Tabori U, Hawkins CE, Bouffet E, Scherer SW, Rutka JT, Malkin D, Clifford SC, Jones SJ, Korbel JO, Pfister SM, Marra MA, Taylor MD
    Subgroup-specific structural variation across 1,000 medulloblastoma genomes.
    Nature , 2012 Aug. 2 : 488(7409)49-56
  • Lee MJ, Hatton BA, Villavicencio EH, Khanna PC, Friedman SD, Ditzler S, Pullar B, Robison K, White KF, Tunkey C, LeBlanc M, Randolph-Habecker J, Knoblaugh SE, Hansen S, Richards A, Wainwright BJ, McGovern K, Olson JM
    Hedgehog pathway inhibitor saridegib (IPI-926) increases lifespan in a mouse medulloblastoma model.
    Proceedings of the National Academy of Sciences of the United States of America , 2012 May 15 : 109(20)7859-64
  • Leary SE, Olson JM
    The molecular classification of medulloblastoma: driving the next generation clinical trials.
    Current opinion in pediatrics , 2012 Feb. : 24(1)33-9
  • Stroud MR, Hansen SJ, Olson JM
    In vivo bio-imaging using chlorotoxin-based conjugates.
    Current pharmaceutical design , 2011 Dec. : 17(38)4362-71
  • Paugh BS, Broniscer A, Qu C, Miller CP, Zhang J, Tatevossian RG, Olson JM, Geyer JR, Chi SN, da Silva NS, Onar-Thomas A, Baker JN, Gajjar A, Ellison DW, Baker SJ
    Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology , 2011 Oct. 20 : 29(30)3999-4006
  • Fouladi M, Stewart CF, Olson J, Wagner LM, Onar-Thomas A, Kocak M, Packer RJ, Goldman S, Gururangan S, Gajjar A, Demuth T, Kun LE, Boyett JM, Gilbertson RJ
    Phase I trial of MK-0752 in children with refractory CNS malignancies: a pediatric brain tumor consortium study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology , 2011 Sept. 10 : 29(26)3529-34
  • Lee SJ, Krauthauser C, Maduskuie V, Fawcett PT, Olson JM, Rajasekaran SA
    Curcumin-induced HDAC inhibition and attenuation of medulloblastoma growth in vitro and in vivo.
    BMC cancer , 2011 Apr, 18 : 11144
  • Cho YJ, Tsherniak A, Tamayo P, Santagata S, Ligon A, Greulich H, Berhoukim R, Amani V, Goumnerova L, Eberhart CG, Lau CC, Olson JM, Gilbertson RJ, Gajjar A, Delattre O, Kool M, Ligon K, Meyerson M, Mesirov JP, Pomeroy SL
    Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology , 2011 Apr, 10 : 29(11)1424-30
  • Wu C, Hansen SJ, Hou Q, Yu J, Zeigler M, Jin Y, Burnham DR, McNeill JD, Olson JM, Chiu DT
    Design of highly emissive polymer dot bioconjugates for in vivo tumor targeting.
    Angewandte Chemie (International ed. in English) , 2011 Apr, 4 : 50(15)3430-4
  • Akcan M, Stroud MR, Hansen SJ, Clark RJ, Daly NL, Craik DJ, Olson JM
    Chemical re-engineering of chlorotoxin improves bioconjugation properties for tumor imaging and targeted therapy.
    Journal of medicinal chemistry , 2011 Feb. 10 : 54(3)782-7
  • Giussani C, Poliakov A, Ferri RT, Plawner LL, Browd SR, Shaw DW, Filardi TZ, Hoeppner C, Geyer JR, Olson JM, Douglas JG, Villavicencio EH, Ellenbogen RG, Ojemann JG
    DTI fiber tracking to differentiate demyelinating diseases from diffuse brain stem glioma.
    NeuroImage , 2010 Aug. 1 : 52(1)217-23
  • Benn CL, Luthi-Carter R, Kuhn A, Sadri-Vakili G, Blankson KL, Dalai SC, Goldstein DR, Spires TL, Pritchard J, Olson JM, van Dellen A, Hannan AJ, Cha JH
    Environmental enrichment reduces neuronal intranuclear inclusion load but has no effect on messenger RNA expression in a mouse model of Huntington disease.
    Journal of neuropathology and experimental neurology , 2010 Aug. : 69(8)817-27
  • Benn CL, Luthi-Carter R, Kuhn A, Sadri-Vakili G, Blankson KL, Dalai SC, Goldstein DR, Spires TL, Pritchard J, Olson JM, van Dellen A, Hannan AJ, Cha JH
    Environmental enrichment reduces neuronal intranuclear inclusion load but has no effect on messenger RNA expression in a mouse model of Huntington disease.
    Journal of neuropathology and experimental neurology , 2010 Aug. : 817-27
  • Hatton BA, Villavicencio EH, Pritchard J, LeBlanc M, Hansen S, Ulrich M, Ditzler S, Pullar B, Stroud MR, Olson JM
    Notch signaling is not essential in sonic hedgehog-activated medulloblastoma.
    Oncogene , 2010 July : 29(26)3865-72
  • Ravanpay AC, Hansen SJ, Olson JM
    Transcriptional inhibition of REST by NeuroD2 during neuronal differentiation.
    Molecular and cellular neurosciences , 2010 June : 44(2)178-89
  • Lee MJ, Veiseh O, Bhattarai N, Sun C, Hansen SJ, Ditzler S, Knoblaugh S, Lee D, Ellenbogen R, Zhang M, Olson JM
    Rapid pharmacokinetic and biodistribution studies using cholorotoxin-conjugated iron oxide nanoparticles: a novel non-radioactive method.
    PloS one , 2010 Mar. : 5(3)e9536
  • Diede SJ, Guenthoer J, Geng LN, Mahoney SE, Marotta M, Olson JM, Tanaka H, Tapscott SJ
    DNA methylation of developmental genes in pediatric medulloblastomas identified by denaturation analysis of methylation differences.
    Proceedings of the National Academy of Sciences of the United States of America , 2010 Jan. : 107(1)234-9
  • Kievit FM, Veiseh O, Bhattarai N, Fang C, Gunn JW, Lee D, Ellenbogen RG, Olson JM, Zhang M
    PEI-PEG-Chitosan Copolymer Coated Iron Oxide Nanoparticles for Safe Gene Delivery: synthesis, complexation, and transfection.
    Advanced functional materials , 2009 July 24 : 19(14)2244-2251
  • James M. Olson, MD, PhD
    Specific targeting of brain tumors with an optical/magnetic resonance imaging nanoprobe across the blood-brain barrier.
    Cancer Res , 2009 : 69(15)
  • Ravanpay AC, Olson JM
    E protein dosage influences brain development more than family member identity.
    Journal of neuroscience research , 2008 May 15 : 1472-81
  • Spiller SE, Ditzler SH, Pullar BJ, Olson JM
    Response of preclinical medulloblastoma models to combination therapy with 13-cis retinoic acid and suberoylanilide hydroxamic acid (SAHA).
    Journal of neuro-oncology , 2008 Apr, : 133-41
  • Hatton BA, Villavicencio EH, Tsuchiya KD, Pritchard JI, Ditzler S, Pullar B, Hansen S, Knoblaugh SE, Lee D, Eberhart CG, Hallahan AR, Olson JM
    The Smo/Smo model: hedgehog-induced medulloblastoma with 90% incidence and leptomeningeal spread.
    Cancer research , 2008 Mar. 15 : 1768-76
  • James M. Olson, MD, PhD
    Tumor-targeted drug delivery and MRI contrast enhancement by chlorotoxin-conjugated iron oxide nanoparticles.
    Nanomedicine , 2008 : 3(4)495-505
  • James M. Olson, MD, PhD
    In vivo MRI detection of gliomas by chlorotoxin-conjugated superparamagnetic nanoprobes.
    Small , 2008 : 4(3)372-379
  • Pritchard JI, Olson JM
    Methylation of PTCH1, the Patched-1 gene, in a panel of primary medulloblastomas.
    Cancer genetics and cytogenetics , 2008 Jan. 1 : 47-50
  • Strand AD, Baquet ZC, Aragaki AK, Holmans P, Yang L, Cleren C, Beal MF, Jones L, Kooperberg C, Olson JM, Jones KR
    Expression profiling of Huntington's disease models suggests that brain-derived neurotrophic factor depletion plays a major role in striatal degeneration.
    The Journal of neuroscience : the official journal of the Society for Neuroscience , 2007 Oct. 24 : 11758-68
  • Prakash A, Piening B, Whiteaker J, Zhang H, Shaffer SA, Martin D, Hohmann L, Cooke K, Olson JM, Hansen S, Flory MR, Lee H, Watts J, Goodlett DR, Aebersold R, Paulovich A, Schwikowski B
    Assessing bias in experiment design for large scale mass spectrometry-based quantitative proteomics.
    Molecular & cellular proteomics : MCP , 2007 Oct. : 1741-8
  • Kuhn A, Goldstein DR, Hodges A, Strand AD, Sengstag T, Kooperberg C, Becanovic K, Pouladi MA, Sathasivam K, Cha JH, Hannan AJ, Hayden MR, Leavitt BR, Dunnett SB, Ferrante RJ, Albin R, Shelbourne P, Delorenzi M, Augood SJ, Faull RL, Olson JM, Bates GP, Jones L, Luthi-Carter R
    Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage.
    Human molecular genetics , 2007 Aug. : 16(15)1845-61
  • Veiseh M, Gabikian P, Bahrami SB, Veiseh O, Zhang M, Hackman RC, Ravanpay AC, Stroud MR, Kusuma Y, Hansen SJ, Kwok D, Munoz NM, Sze RW, Grady WM, Greenberg NM, Ellenbogen RG, Olson JM
    Tumor paint: a chlorotoxin:Cy5.5 bioconjugate for intraoperative visualization of cancer foci.
    Cancer research , 2007 July 15 : 6882-8
  • Kaltenbach LS, Romero E, Becklin RR, Chettier R, Bell R, Phansalkar A, Strand A, Torcassi C, Savage J, Hurlburt A, Cha GH, Ukani L, Chepanoske CL, Zhen Y, Sahasrabudhe S, Olson J, Kurschner C, Ellerby LM, Peltier JM, Botas J, Hughes RE
    Huntingtin interacting proteins are genetic modifiers of neurodegeneration.
    PLoS genetics , 2007 May 11 : 3(5)e82
  • Strand AD, Aragaki AK, Baquet ZC, Hodges A, Cunningham P, Holmans P, Jones KR, Jones L, Kooperberg C, Olson JM
    Conservation of regional gene expression in mouse and human brain.
    PLoS genetics , 2007 Apr, 20 : 3(4)e59
  • Spiller SE, Ravanpay AC, Hahn AW, Olson JM
    Suberoylanilide hydroxamic acid is effective in preclinical studies of medulloblastoma.
    Journal of neuro-oncology , 2006 Sept. : 259-70
  • Hatton BA, Knoepfler PS, Kenney AM, Rowitch DH, de Alborán IM, Olson JM, Eisenman RN
    N-myc is an essential downstream effector of Shh signaling during both normal and neoplastic cerebellar growth.
    Cancer research , 2006 Sept. 1 : 8655-61
  • Lin CH, Tapscott SJ, Olson JM
    Congenital hypothyroidism (cretinism) in neuroD2-deficient mice.
    Molecular and cellular biology , 2006 June : 4311-5
  • Jones L, Goldstein DR, Hughes G, Strand AD, Collin F, Dunnett SB, Kooperberg C, Aragaki A, Olson JM, Augood SJ, Faull RL, Luthi-Carter R, Moskvina V, Hodges AK
    Assessment of the relationship between pre-chip and post-chip quality measures for Affymetrix GeneChip expression data.
    BMC bioinformatics , 2006 Apr, 19 : 211
  • Fan W, Khalid N, Hallahan AR, Olson JM, Zhao LP
    A statistical method for predicting splice variants between two groups of samples using GeneChip expression array data.
    Theoretical biology & medical modelling , 2006 Apr, 7 : 19
  • Hodges A, Strand AD, Aragaki AK, Kuhn A, Sengstag T, Hughes G, Elliston LA, Hartog C, Goldstein DR, Thu D, Hollingsworth ZR, Collin F, Synek B, Holmans PA, Young AB, Wexler NS, Delorenzi M, Kooperberg C, Augood SJ, Faull RL, Olson JM, Jones L, Luthi-Carter R
    Regional and cellular gene expression changes in human Huntington's disease brain.
    Human molecular genetics , 2006 Mar. 15 : 965-77
  • Ince-Dunn G, Hall BJ, Hu SC, Ripley B, Huganir RL, Olson JM, Tapscott SJ, Ghosh A
    Regulation of thalamocortical patterning and synaptic maturation by NeuroD2.
    Neuron , 2006 Mar. 2 : 683-95
  • Apostol BL, Illes K, Pallos J, Bodai L, Wu J, Strand A, Schweitzer ES, Olson JM, Kazantsev A, Marsh JL, Thompson LM
    Mutant huntingtin alters MAPK signaling pathways in PC12 and striatal cells: ERK1/2 protects against mutant huntingtin-associated toxicity.
    Human molecular genetics , 2006 Jan. 15 : 273-85
  • James M. Olson, MD, PhD
    Nervous system cancer models: medulloblastoma.
    Drug Discovery Today: Disease Models , 2006 : 3(2)167-74
  • James M. Olson, MD, PhD
    Regional and cellular gene expression changes in human Huntington's disease brain.
    Human Molecular Genetics , 2006 : 15(6)965-77
  • Douglas JG, Rockhill JK, Olson JM, Ellenbogen RG, Geyer JR
    Cisplatin-based chemotherapy followed by focal, reduced-dose irradiation for pediatric primary central nervous system germinomas.
    Journal of pediatric hematology/oncology : official journal of the American Society of Pediatric Hematology/Oncology , 2006 Jan. : 36-9
  • Valenza M, Rigamonti D, Goffredo D, Zuccato C, Fenu S, Jamot L, Strand A, Tarditi A, Woodman B, Racchi M, Mariotti C, Di Donato S, Corsini A, Bates G, Pruss R, Olson JM, Sipione S, Tartari M, Cattaneo E
    Dysfunction of the cholesterol biosynthetic pathway in Huntington's disease.
    The Journal of neuroscience : the official journal of the Society for Neuroscience , 2005 Oct. 26 : 9932-9
  • Benn CL, Landles C, Li H, Strand AD, Woodman B, Sathasivam K, Li SH, Ghazi-Noori S, Hockly E, Faruque SM, Cha JH, Sharpe PT, Olson JM, Li XJ, Bates GP
    Contribution of nuclear and extranuclear polyQ to neurological phenotypes in mouse models of Huntington's disease.
    Human molecular genetics , 2005 Oct. 15 : 3065-78
  • Lin CH, Hansen S, Wang Z, Storm DR, Tapscott SJ, Olson JM
    The dosage of the neuroD2 transcription factor regulates amygdala development and emotional learning.
    Proceedings of the National Academy of Sciences of the United States of America , 2005 Oct. 11 : 14877-82
  • Kooperberg C, Aragaki A, Strand AD, Olson JM
    Significance testing for small microarray experiments.
    Statistics in medicine , 2005 Aug. 15 : 2281-98
  • Strand AD, Aragaki AK, Shaw D, Bird T, Holton J, Turner C, Tapscott SJ, Tabrizi SJ, Schapira AH, Kooperberg C, Olson JM
    Gene expression in Huntington's disease skeletal muscle: a potential biomarker.
    Human molecular genetics , 2005 July 1 : 1863-76
  • Fan W, Pritchard JI, Olson JM, Khalid N, Zhao LP
    A class of models for analyzing GeneChip gene expression analysis array data.
    BMC genomics , 2005 Feb. 14 : 16
  • James M. Olson, MD, PhD
    An optical and MRI multifunctional nanoprobe for targeting gliomas.
    Nano Letters , 2005 : 5(6)1003-1008
  • Hallahan AR, Pritchard JI, Hansen S, Benson M, Stoeck J, Hatton BA, Russell TL, Ellenbogen RG, Bernstein ID, Beachy PA, Olson JM
    The SmoA1 mouse model reveals that notch signaling is critical for the growth and survival of sonic hedgehog-induced medulloblastomas.
    Cancer research , 2004 Nov. 1 : 7794-800
  • Olson JM, Hallahan AR
    p38 MAP kinase: a convergence point in cancer therapy.
    Trends in molecular medicine , 2004 Mar. : 125-9
  • Lin CH, Stoeck J, Ravanpay AC, Guillemot F, Tapscott SJ, Olson JM
    Regulation of neuroD2 expression in mouse brain.
    Developmental biology , 2004 Jan. 1 : 234-45
  • Oh MK, Scoles DR, Haipek C, Strand AD, Gutmann DH, Olson JM, Pulst SM
    Genetic heterogeneity of stably transfected cell lines revealed by expression profiling with oligonucleotide microarrays.
    Journal of cellular biochemistry , 2003 Dec. 1 : 1068-78
  • Hallahan AR, Pritchard JI, Chandraratna RA, Ellenbogen RG, Geyer JR, Overland RP, Strand AD, Tapscott SJ, Olson JM
    BMP-2 mediates retinoid-induced apoptosis in medulloblastoma cells through a paracrine effect.
    Nature medicine , 2003 Aug. : 1033-8
  • Strand AD, Olson JM, Kooperberg C
    Estimating the statistical significance of gene expression changes observed with oligonucleotide arrays.
    Human molecular genetics , 2002 Sept. 15 : 2207-21
  • Kooperberg C, Sipione S, LeBlanc M, Strand AD, Cattaneo E, Olson JM
    Evaluating test statistics to select interesting genes in microarray experiments.
    Human molecular genetics , 2002 Sept. 15 : 2223-32
  • Berman DM, Karhadkar SS, Hallahan AR, Pritchard JI, Eberhart CG, Watkins DN, Chen JK, Cooper MK, Taipale J, Olson JM, Beachy PA
    Medulloblastoma growth inhibition by hedgehog pathway blockade.
    Science (New York, N.Y.) , 2002 Aug. 30 : 1559-61
  • Luthi-Carter R, Hanson SA, Strand AD, Bergstrom DA, Chun W, Peters NL, Woods AM, Chan EY, Kooperberg C, Krainc D, Young AB, Tapscott SJ, Olson JM
    Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain.
    Human molecular genetics , 2002 Aug. 15 : 1911-26
  • Luthi-Carter R, Strand AD, Hanson SA, Kooperberg C, Schilling G, La Spada AR, Merry DE, Young AB, Ross CA, Borchelt DR, Olson JM
    Polyglutamine and transcription: gene expression changes shared by DRPLA and Huntington's disease mouse models reveal context-independent effects.
    Human molecular genetics , 2002 Aug. 15 : 1927-37
  • Chan EY, Luthi-Carter R, Strand A, Solano SM, Hanson SA, DeJohn MM, Kooperberg C, Chase KO, DiFiglia M, Young AB, Leavitt BR, Cha JH, Aronin N, Hayden MR, Olson JM
    Increased huntingtin protein length reduces the number of polyglutamine-induced gene expression changes in mouse models of Huntington's disease.
    Human molecular genetics , 2002 Aug. 15 : 1939-51
  • Sipione S, Rigamonti D, Valenza M, Zuccato C, Conti L, Pritchard J, Kooperberg C, Olson JM, Cattaneo E
    Early transcriptional profiles in huntingtin-inducible striatal cells by microarray analyses.
    Human molecular genetics , 2002 Aug. 15 : 1953-65
  • Lieberman AP, Harmison G, Strand AD, Olson JM, Fischbeck KH
    Altered transcriptional regulation in cells expressing the expanded polyglutamine androgen receptor.
    Human molecular genetics , 2002 Aug. 15 : 1967-76
  • Xu XL, Olson JM, Zhao LP
    A regression-based method to identify differentially expressed genes in microarray time course studies and its application in an inducible Huntington's disease transgenic model.
    Human molecular genetics , 2002 Aug. 15 : 1977-85
  • Pomeroy SL, Tamayo P, Gaasenbeek M, Sturla LM, Angelo M, McLaughlin ME, Kim JY, Goumnerova LC, Black PM, Lau C, Allen JC, Zagzag D, Olson JM, Curran T, Wetmore C, Biegel JA, Poggio T, Mukherjee S, Rifkin R, Califano A, Stolovitzky G, Louis DN, Mesirov JP, Lander ES, Golub TR
    Prediction of central nervous system embryonal tumour outcome based on gene expression.
    Nature , 2002 Jan. 24 : 436-42
  • Hughes RE, Lo RS, Davis C, Strand AD, Neal CL, Olson JM, Fields S
    Altered transcription in yeast expressing expanded polyglutamine.
    Proceedings of the National Academy of Sciences of the United States of America , 2001 Nov. 6 : 98(23)13201-6
  • Thomas JG, Olson JM, Tapscott SJ, Zhao LP
    An efficient and robust statistical modeling approach to discover differentially expressed genes using genomic expression profiles.
    Genome research , 2001 July : 11(7)1227-36
  • Olson JM, Asakura A, Snider L, Hawkes R, Strand A, Stoeck J, Hallahan A, Pritchard J, Tapscott SJ
    NeuroD2 is necessary for development and survival of central nervous system neurons.
    Developmental biology , 2001 June 1 : 234(1)174-87
  • Johnston DL, Olson JM, Benjamin DR
    Gastrointestinal stromal tumor in a patient with previous neuroblastoma.
    Journal of pediatric hematology/oncology , 2001 May : 23(4)255-6
  • Hughes RE, Olson JM
    Therapeutic opportunities in polyglutamine disease.
    Nature medicine , 2001 Apr, : 7(4)419-23
  • James M. Olson, MD, PhD
    The Hereditary Disease Array Group (HDAG) - Microarrays, Models and Mechanisms: A Collaboration Update.
    Current Genomics , 2001 : (2)221-229
  • Luthi-Carter R, Strand A, Peters NL, Solano SM, Hollingsworth ZR, Menon AS, Frey AS, Spektor BS, Penney EB, Schilling G, Ross CA, Borchelt DR, Tapscott SJ, Young AB, Cha JH, Olson JM
    Decreased expression of striatal signaling genes in a mouse model of Huntington's disease.
    Human molecular genetics , 2000 May 22 : 9(9)1259-71
  • Farah MH, Olson JM, Sucic HB, Hume RI, Tapscott SJ, Turner DL
    Generation of neurons by transient expression of neural bHLH proteins in mammalian cells.
    Development (Cambridge, England) , 2000 Feb. : 127(4)693-702
  • Gropman AL, Packer RJ, Nicholson HS, Vezina LG, Jakacki R, Geyer R, Olson JM, Phillips P, Needle M, Broxson EH Jr, Reaman G, Finlay J
    Treatment of diencephalic syndrome with chemotherapy: growth, tumor response, and long term control.
    Cancer , 1998 July 1 : 83(1)166-72
  • Rostomily RC, Bermingham-McDonogh O, Berger MS, Tapscott SJ, Reh TA, Olson JM
    Expression of neurogenic basic helix-loop-helix genes in primitive neuroectodermal tumors.
    Cancer research , 1997 Aug. 15 : 57(16)3526-31
  • Tapscott SJ, Miller AD, Olson JM, Berger MS, Groudine M, Spence AM
    Gene therapy of rat 9L gliosarcoma tumors by transduction with selectable genes does not require drug selection.
    Proceedings of the National Academy of Sciences of the United States of America , 1994 Aug. 16 : 91(17)8185-9
  • James M. Olson, MD, PhD
    Localization of PK 11195 binding sites to mitochondria of human glioma cells.
    J. Neuro-Oncology , 1992 : (13)32-42
  • James M. Olson, MD, PhD
    Positron emission tomographic imaging of human gliomas with ligands for the peripheral benzodiazepine binding site.
    Annals Neurol. , 1989 : (26)752-758
  • James M. Olson, MD, PhD
    Presence of peripheral-type benzodiazepine binding sites on human erythrocytes.
    Eur. J. Pharmacol. , 1988 : (152)47-53
  • James M. Olson, MD, PhD
    Autoradiographic localization of cerebellar excitatory amino acid binding sites in the mouse.
    Neurosci. , 1987 : 22913-923
  • James M. Olson, MD, PhD
    Autoradiographic characterization of N-Methyl-D-Aspartate-, quisqualate-, and kainate-sensitive glutamate binding sites
    J. Pharmacol. Exp. Ther. , 1985 : 233254-263
  • James M. Olson, MD, PhD
    Development and Evaluation of Chlorotoxin-based Tumor-specific Molecular Imaging Probes

Research Funding

Grant Title Grantor Amount Award Date
NSF1208554 (Seibel, PI) NSF/University of Washington $19,790, effort: 0.24 calendar Sept. 1, 2012 - Aug. 30, 2016
Pilot Funds FHCRC (Olson, PI) Institutional Funds $200,000, effort: 0.24 calendar July 1, 2012 - June 30, 2013
2R01CA114567-06A1 (Olson, PI) NIH NCI $129,143, effort: 1.8 calendar April 18, 2012 - March 31, 2017
Contract (Olson, PI) Sanofi Aventis $336,303 (no-cost extension), effort: 0.36 calendar Oct. 27, 2011 - Feb. 28, 2013
CA100735 (Paddison, PI) Department of Defense / CDMRP $89,402, effort: 0.24 calendar Sept. 1, 2011 - Aug. 31, 2014
1R01CA155360-01 (Olson, PI) NIH NCI $207,500, effort: 0.24 calendar June 7, 2011 - March 31, 2016
4R42CA14410-02 (Olson, PI) NIH NCI $441,641 (Phase II), effort: 1.2 calendar May 1, 2011 - Dec. 16, 2012
Contract (Olson, PI) Presage Biosciences, Inc. $53,409, effort: 0.24 calendar Nov. 1, 2009 - Dec. 16, 2012
5U10 CA98543-09 (Adamson, PI) NCCF COG $12,294 (subcontract), effort: 0.58 calendar March 1, 2005 - Feb. 28, 2014
Overlap